Overview
Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This 39-week, open label study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2360 study.Phase:
Phase 3Details
Lead Sponsor:
NovartisTreatments:
Celecoxib
Diclofenac
Lumiracoxib
Criteria
Inclusion Criteria:- Have completed the core CCOX189A2360 study
- Males and females over the 18 years old
Exclusion Criteria:
- Treatment in the extension study is not considered appropriate by the treating
physician
- Non-compliance or major protocol violation of the core study
Other protocol-defined inclusion/exclusion criteria may apply